Background: Many patients with colorectal cancer are elderly with competing comorbidities. When constructing nomogram for assessing survival, we should consider the influence of competing risk. A competing-risks nomogram was developed to estimate the probability of death due to colorectal cancer for patients after curative surgery. Methods: A total of 2442 patients with non-metastatic colorectal cancer were included to develop competing-risks nomogram. Competing-risks nomogram were established based on the results of Fine and Gray competing-risks proportional hazards model. To maximize the accuracy of prediction, model selection was not carried out, and non-linear continuous variables were flexibly modeled with restricted cubic splines. The nomogram was internal-validated by bootstrapping, and externally validated with a separate database of 299 patients from The Cancer Genome Atlas. The performance of this model was assessed by concordance index and a calibration curve. Results: There were 332 patients died of colorectal cancer and 46 died of other causes during the follow-up period. Age, T stage, N stage, histological type, tumor location, adjuvant chemotherapy, preoperative carcinoembryonic antigen, lymph vascular invasion, lymph node ratio and sample lymph nodes were integrated into competing-risks nomogram. The competing-risks nomogram for predicting probability of death due to colorectal cancer with a concordance index of 0.768, ameliorating the stratification provided by the seventh edition tumor-node-metastasis staging system of the American Joint Committee on Cancer (AJCC). The concordance index for validation dataset was 0.783. Conclusion: We developed and externally validated a competing-risks nomogram for Chinese Han patients with non-metastatic colorectal cancer, which could provide probability of death from colorectal cancer in the presence of competing risks.
Introduction
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, its morbidity and mortality are third and fourth, respectively (1, 2) . Colonoscopy and colon polypectomy are widely used in some developed countries, the incidence of CRC shows a steady downward trend (3) . However, with the rapid development of China's economy and the improvement of the quality of national life, the incidence and mortality of CRC have increased in the population of our country. Despite advances in chemotherapy, which include new cytotoxic and molecular targeted therapies, the clinical effect is not ideal due to local recurrence or distant metastasis (4) . Therefore, accurate prognosis prediction is of great significance for improving the prognosis of CRC patients and selecting appropriate treatment.
The classic tumor-node-metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) is still an important reference for CRC prognosis and individualized treatment. TNM staging combined with pathological results, intraoperative conditions, and the results of auxiliary examination to reflect the overall situation of the tumor, but it still has some limitations in the prognosis evaluation. The prognosis of CRC patients with the same stage, the same pathological type and the same treatment scheme has great difference. In addition to TNM staging system, many prognostic factors have been identified, including clinicopathological factors, such as tumor location, histological type and degree of differentiation; some inflammation biomarkers have also been confirmed to be associated with the prognosis of CRC (5, 6) . Many molecular factors, such as microsatellite status and RAS/RAF mutation, also have important prognostic value, but sophisticated and expensive laboratory techniques have limited their applications (7) (8) (9) (10) . Nomogram is an effective tool to visualize the regression model (11, 12) , which can integrate multiple prognostic factors and has achieved high prediction accuracy. In many studies, nomogram has been successfully applied to oncology prognosis. Most of the prognostic nomogram is based on the Cox proportional hazards model (13) (14) (15) .
Many patients with CRC are elderly and have competing comorbidities. Therefore, the outcome of patients is not only dying of CRC but also likely to die from other competing comorbidities. We define non-CRC death as a competing risk, which often affects the probability of the research outcome or cause it to no longer occur. The Cox proportional hazards regression model treats competing outcomes as censoring, ignoring the impact of competing risks. However, when constructing a nomogram, we should consider the impact of competition risk, otherwise it will inevitably cause inaccurate estimation of their individual absolute risk (16, 17) .
This study aimed at using common prognostic factors to construct a competing-risks nomogram based on the results of Fine and Gray competing-risks proportional hazards model. It is expected that the nomogram will provide more individualized results' prediction, which can help clinicians and patients to make treatment decisions.
Materials and methods

Study population
The main inclusion criteria for this study were as follows: (i) diagnosed as CRC according to histology or cytology, (ii) at least 18 years old, (iii) patients had not received neoadjuvant therapy (iv) having had radical surgery, (v) available of follow-up data, (vi) preoperative biochemical test data can be obtained. The following exclusion criteria were used for our study: (i) emergency and untreatable due to widespread metastasis, (ii) combined with other cancers and (iii) receiving preoperative chemotherapy or immunotherapy. Then there were 2442 eligible patients diagnosed with CRC in Shandong provincial hospital between November 2010 and July 2016 were enrolled into the study. 5-FU-based adjuvant chemotherapy is recommended for II high-risk patients and Stage III patients. This study was approved by the Ethics Committee of School of Public Health, Shandong University and conducted in accordance with the ethical guidelines of the Declaration of Helsinki of the World Medical Association.
We extracted their baseline clinicopathologic characteristics from patients' electronic medical records, the clinicopathologic characteristics of these patients including age, gender, tumor location, T stage, N stage, histological type. TNM stage was determined according to the TNM staging system of AJCC. Neutrophils, lymphocytes, mononuclear cells and platelet counts were collected from the laboratory blood biochemical test, and the albumin level was collected from the hepatic function test.
In this study, all entries of participants were searched in the database of death registration and medical insurance in Shandong province by patient ID number. By this way, we collected survival and treatment information of those patients, such as survival state, death time and the cause of death. In addition to this way, we also use the telephone or email for follow-up. Survival time was defined as the time elapsed from the date of pathological diagnosis to the time of death due to CRC. Deaths due to other causes are defined as competing outcomes. Patients who did not die at the time of the last follow-up were censored.
To test the generalization of the model, we use The Cancer Genome Atlas (TCGA) Colon and Rectal cancer (COADREAD) database as an external validation data. There are 630 patients in the COADREAD database having survival data. According to the abovementioned exclusion conditions, only patients with surgically resected, non-metastatic disease were included, and all patients were required to have sufficient information to score all variables in the established nomogram. Finally, a total of 299 patients were included in the validation dataset.
Methods
We used cumulative incidence estimated by cumulative incidence function (CIF) to describe cause-specific survival, and Gray's test was used to test for cause-specific survival differences (17) . We classified cause of death as either CRC or other causes. The competition risk model is used to estimate the probability of death due to CRC, which accounts for the fact that individuals can only have one of the two competing outcomes.
In developing the competing-risks nomogram, it estimates a scoring for each level of every variable according to the model coefficient, and a total score can be calculated for each patient, the probability of each patient's outcome at a specific time is calculated by the conversion function between the score and the probability of the occurrence of the outcome. To maximize the accuracy of prediction, variable selection is not carried out (18) and non-linear continuous variables were flexibly modeled with restricted cubic splines (19) .
Kattan et al. (18) provide a calibration method to assess the predictive accuracy of our nomogram model. We estimated the probability of death from CRC at 5 and 3 years for everyone, respectively, fitting the competing-risk nomogram model established by using data only from the other 2442 individuals. Given the size of the dataset, we divide the data into four parts according to the quartiles of prediction probability. Individuals within each quantile are used to calculate the marginal cumulative incidence using CIF described by Gray (17) . we also calculated the mean predicted probability of death from CRC. Then we plotted a calibration plot to compare the mean predicted probabilities to the non-model-based marginal cumulative incidence within each quartile. The cumulative incidence/predicted probability pairs fall along the 45°line through the origin means that competing-risks nomogram is a wellcalibrated model. Because of the existence of competing outcomes, it is problematic to use concordance index (C-index) to evaluate the accuracy of nomogram (20) . In this study we use 1-probability of death from CRC to calculate C-index to approximate estimated the accuracy of the model. Bootstrapping was used to internally validation of the model.
All statistical analyses were performed using R software (R version 3.4.3) with rms, cmprsk and mstate packages (https://cran.rproject.org/).
Results
Patients' baseline characteristics
A total of 2442 eligible patients with CRC were included in this study. The median age is 61 (IQR 52-69) years old. A total of 870 (35.63%) patients were diagnosed as colon cancer and 1572 (64.37%) as rectal cancer. The median follow-up time was 19.77 months with 332 patients died of CRC and 46 other causes death.
According to TNM staging system of AJCC, T1, T2, T3 and T4 stages accounted for 128 (5.24%), 388 (15.89%), 592 (24.24) and 1334 (54.63%), respectively, and N0, N1 and N2 stages accounted for 1489 (60.97%), 533 (21.83%) and 420 (17.20%), respectively. Most patients (2115, 86.61%) were confirmed as adenocarcinoma, while 327 (13.39%) patients were confirmed as mucous mucinous adenocarcinoma. All patients underwent radical resection of primary tumor, and 1095 (44.84%) patients received adjuvant chemotherapy. The cumulative incidence stratified by clinicopathological parameters is shown in Table 1 . We can find that some clinicopathological factors were associated with the cumulative incidence of CRC death, such as age, differentiation, histological type, T stage, N stage, sample lymph nodes, carcinoembryonic antigen (CEA), CA19-9, lymph node ratio (LNR) and lymph vascular invasion. Five-year marginal cumulative incidence of CRC death and othercause death were 33.28 and 3.82%, respectively. 
Nomogram and validation
We constructed a nomogram to calculate the probability of colorectal death by using common clinicopathological factors. To maximize the accuracy of prediction, model selection is not carried out, which is similar to the work of others in the past (18, 21) and non-linear continuous variables were flexibly modeled with restricted cubic splines with three knots at the 10, 50 and 90% empirical quantiles. Considering the availability of preoperative CA19-9 and differentiation in the validation dataset, we excluded preoperative CA19-9 and differentiation in the final nomogram. Although the tumor location and adjuvant chemotherapy were not statistically significant in Gray's test, we integrated it to multivariate analysis for reference to other studies. Finally, age, T stage, N stage, histological type, tumor location, adjuvant chemotherapy, preoperative CEA, lymph vascular invasion, LNR and sample lymph nodes were integrated into competing-risks nomogram. As shown in Fig. 1 and Table 2 , because different prognostic factors and different levels of the same prognostic factor are of different importance in predicting prognosis, different scores have been assigned according to the model results. We found that the impact of age on prognosis is negligible for CRC patients which below 60 years of age; when CEA level is above 100 μg/ml, the effect of higher CEA on prognosis of patients with CRC is almost unchanged. In addition, nomogram scores showed that T stage, LNR, age and CEA levels had a greater impact on the prognosis of CRC patients than other factors. In the training dataset, the C-index of the competing-risks nomogram is 0.768 (95% CI: 0.737-0.799), and 0.774 (95% CI: 0.773-0.776) for bootstrapping, which was superior to predictions based on the seventh edition TNM staging system of AJCC, with Cindex of 0.686 (95% CI: 0.651-0.721). In the external validation dataset, the index of the nomogram was 0.783 (95% CI: 0.710-0.856). Calibration plot can intuitively show the relationship between predicted risk value and actual risk value. Figure 2 depicts the results of the model calibration, X-axis is mean predicted probabilities of CRC death estimated by competing-risks nomogram, Y-axis is the marginal cumulative incidence probability for CRC death. Plotting symbol is a combination of year of prediction (numeric) and quartile (a letter). For example, point '3c' is the third quartile of the 3-year nomogram predictions. Dash line represents equality between predicted probabilities estimated by nomogram and observed marginal cumulative incidence. We could find that triangles are all close to the 45°line, which means that the nomogram-predicted probabilities of death are in good agreement with the marginal cumulative incidence. In other words, the nomogram is well calibrated.
The performance of the nomogram in stratifying risk of patients within each of the TNM stages is illustrated in two ways. First, we plotted a histogram of nomogram-predicted probabilities within each of the TNM stages and depicted the variation in predicted outcome within each of the TNM stages (Fig. 3) . The second way is the comparison of cumulative incidence curves by identifying the highrisk and low-risk patients within each of the TNM stages. We divided the patients into high-risk group and low-risk group according to the median of the predicted probability within each of TNM stage. We divided the patients into high-risk group and low-risk group according to the mean predicted probability within each of the TNM stages. Then the cumulative incidence curve stratified by risk groups within each TNM stage was plotted (Fig. 4) . Given the size of the dataset, subgroups with fewer than 30 patients were omitted from the graphs.
Discussion
In this study, based on the results of Fine and Gray competing-risks proportional hazards model, we constructed a competing-risks nomogram to predict probability of CRC death for patients with non-metastatic CRC receiving radical resection.
To the best of our knowledge, this is the first competing-risks nomogram for predicting probability of CRC death for patients with resected surgery. Many patients with CRC are elderly and have competing comorbidities. Therefore, the outcome of patients is not only dying of CRC but also likely to die from other competing comorbidities. Rather than providing the patient with his probability of dying from CRC assuming other-cause death is either removed or processed as censored, we provide the patient with his probability of dying from CRC given that he is also at risk of dying from other causes. These competing causes of death are potentially related to but not directly attributable to the CRC, which may be the reason that T staging and N staging are associated with other causes of death. In addition, some studies also take account of the interaction between chemotherapy, T staging and number of positive lymph node and incorporate it into nomogram (22) , but in this study, we cautiously decided not to include this factor in the final nomogram because the C-index improved by only 0.003 after adding it to the current model. Age, T stage, N stage, histological type, tumor location, adjuvant chemotherapy, preoperative CEA, lymph vascular invasion, LNR and sample lymph nodes were finally incorporated into competingrisks nomograms. There are plenty of previous studies which had reported that these clinicopathological factors associated with the prognosis of patients with CRC (23) (24) (25) (26) (27) (28) (29) (30) . It is worth noting that many papers had reported that the number of sample lymph nodes was an important prognostic factor for many cancers (31) (32) (33) , and some similar studies also found that there was a significant relationship between higher number of examined lymph nodes and better survival (22, 34) . One of the possible reasons is that with more extensive sampling of lymph nodes, more potential metastasized lymph nodes will be cleared out. Moreover, complete sampling of lymph nodes means a more accurate pathology results can be used in precise staging, therefore, appropriate adjuvant treatments for patients. In addition, LNR integrates information about the number of positive lymph nodes and the number of sample lymph nodes, and many studies reported that LNR was superior to the number of positive lymph nodes in predicting prognosis in patients with cancers (35) (36) (37) (38) . In contrast to the TNM staging system based on the depth of infiltration and the number of positive lymph nodes, the nomogram can integrate a variety of prognostic factors to make more personalized predictions for the patients. Non-linear continuous variables can be flexibly modeled with restricted cubic splines. Nomogram includes non-linear and more complex relations. Therefore, it is not surprising that the performance of nomogram is better than the TNM staging system of AJCC. There are several nomograms that are based on Cox proportional hazards regression model have been constructed to predict survival for patients with CRC, but the predictive accuracy is not entirely satisfactory. (35) . In this study, the model is also validated by the COADREAD dataset, which consisted of patients from America. The C-index of validation dataset is 0.783 (95% CI: 0.710-0.856), which means that the established nomogram has optimal generalizability.
Nomogram integrates common clinicopathological factors to provide more personalized prognostic predictions than the AJCC classification system. With this easy-to-use scoring system, doctors and patients can make individual survival predictions after surgery. Identifying patients with different survival risks may have an impact on treatment or choice of care. Patients requiring additional treatment or intensive follow-up are still controversial, this scoring system may be a solution. There are some limitations in our study. First, the patients with CRC included in this study were from a single center and all patients in this study were retrospectively enrolled from Shandong province. Second, because of the retrospective Figure 4 . Marginal cumulative incidence curves for death from CRC stratified by the mean predicted probability within each of the TNM stages, subgroups with fewer than 30 patients were omitted from the graphs.
design of the study, some recognized prognostic parameters are unavailable, such as perforation. MMR status and RAS/RAF status are recognized as important prognostic factors, but due to the family's economic conditions and the cost of the examination, most of Chinese patients cannot afford it, it is difficult for us to obtain these data. In addition, considering the availability of some prognostic factors in the validation dataset, we excluded some recognized prognostic parameters in the final nomogram, such as CA19-9, perineural infiltration.
In conclusion, we developed and externally validated a competing-risks nomogram for Chinese Han patients with nonmetastatic CRC, which could provide the probability of death from CRC in the presence of competing risks. The competingrisks nomogram takes full account of the impact of competing risks, providing more personalized prognosis prediction than that provided by AJCC classification system. It can help clinicians and patients to make treatment decisions.
